Notably, a point mutation in MAP3K14 was identified in a MCL sample (P13-P), which further suggests that genetic characterization of the tumor genome will be important for the choice of therapeutic strategy for MCL patients. The gene discussed is MAP3K14; the disease is mantle cell lymphoma.